CTX.TO (Mkap C$ 7.7 M) 1x FDA approved /2x Phase 3 und weitere Produkte am Markt

[Jim_Panse]

Antwort auf Beitrag Nr.: 75.445.929 von Niller84 am 13.03.24 15:06:06

Hört sich im Moment leider alles sehr vage an. Und ob sie den weggebrochenen Umsatz so schnell mit anderen Kunden auffangen können, bleibt abzuwarten.

Auf der anderen Seite werden weiter Aktien zurückgekauft und der Cashbestand hat sich auf Jahressicht trotzdem weiter auf 9,4 Mio. C$ erhöht (auch aufgrund von EInmaleffekten). Und das bei einer MCap von gerade mal 7,7 Mio C$.

Wenn hier wieder positive News kommen, sollte es schnell nach oben gehen...

[Niller84]

Antwort auf Beitrag Nr.: 75.037.155 von Jim_Panse am 02.01.24 10:01:20

@Jim_Panse
So wie ich es verstanden habe, ist durch die Veränderung im Management bei einem ihrer Hauptabnehmer für ihre manufactoring Sparte ein Großteil des Umsatzes weggebrochen. Dadurch ist Crescita in die verlustzone gerutscht und die Aktie begleitet eine enorme Unsicherheit. Hier ein Auszug aus dem gerade veröffentlichten Bericht für Q4 2023.
"Update on Manufacturing Segment
Certain manufacturing orders initially scheduled to be delivered in the second half of fiscal 2023 were, in part, deferred to 2024, and some cancelled, contributing to a material decrease in our manufacturing segment revenue for Q4-2023 and fiscal 2023, compared to the same periods of 2022. While our customer is reassessing commercial options for their products in key markets, we continue to have discussions regarding manufacturing opportunities to support their growth plans going forward."
Sehr wahrscheinlich wird es Crescita in Q1 2024 wieder in die gewinnzone schaffen, denn die SkinCare Sparte wächst und die Verschobenen Aufträge sollten den Umsatz in der manufactoring Sparte wieder erhöhen. Ich setze hier mal wieder einen Fuß in die Tür und werde gegebenfalls vor den Q1 Zahlen aufstocken.

https://crescita2021tf.q4web.com/news/news-details/2024/Cres…

[Jim_Panse]

Frohes neues Jahr

...oder ist das hier eher auszuschließen nach den letzten News im Oktober?

Wie ist eure Meinung?

[Jim_Panse]

Crescita Reports Third Quarter 2022 Results

Sales Doubled with New Manufacturing Revenue Record of $4.3M

Adjusted EBITDA1 of $0.5M, up $1.0M Year-over-Year

Cash Balance of $10.7M

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the third quarter ended September 30, 2022 (“Q3-F2022”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted.

Financial Highlights

Q3-F2022 vs. Q3-F2021

Revenue was $6,032 compared to $2,993, up $3,039;
Gross profit was $2,938 compared to $1,525, up $1,413;
Operating expenses were $2,805 compared to $2,385, up $420;
Adjusted EBITDA1 was $512 compared to $(471), up $983;
Ending cash was $10,738, up $236 for the quarter.

https://finance.yahoo.com/news/crescita-reports-third-quarte…

[pickuru]

Q2-F2022 Corporate Developments

Approval of ART FILLER® Injectables

Health Canada approved the following hyaluronic acid ("HA") injectables (the "Fillers") for treating lines and wrinkles, replacing skin volume, and plumping and defining face contours: Art Filler Universal, Art Filler Fine Lines, and Art Filler Contour. We expect to launch the Fillers in the Canadian medical aesthetic market with a dedicated sales force in the fourth quarter of 2022...

https://finance.yahoo.com/news/crescita-reports-second-quart…

[Jim_Panse]

Crescita Reports Second Quarter 2022 Results

Over 120% sales growth with Record Manufacturing Revenue of $3.9M

Adjusted EBITDA1 of $0.6M, up $0.9M Year-over-Year

Repayment of $1.0 M of Convertible Debentures

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the second quarter ended June 30, 2022 (“Q2-F2022”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted.

Financial Highlights

Q2-F2022 vs. Q2-F2021

Revenue was $6,512 compared to $2,949, up $3,563;
Gross profit was $3,647 compared to $1,722, up $1,925;
Operating expenses were $3,447 compared to $2,399, up $1,048;
Adjusted EBITDA1 was $646 compared to $(269), up $915;
Ending cash was $10,502, down $1,240 for the quarter.

https://www.crescitatherapeutics.com/press-releases

[Jim_Panse]

Antwort auf Beitrag Nr.: 71.175.496 von pickuru am 23.03.22 15:24:12

Wenn's in 2022 so weiter geht wie in Q4, sollte 1$ wirklich nur das 1. Kursziel sein...

Financial Highlights

Q4-F2021 vs. Q4-F2020

Revenue was $7,562 compared to $2,791, up $4,771;
Gross profit was $4,651 compared to $1,588, up $3,063;
Operating expenses were $3,536 compared to $2,316, up $1,220;
Adjusted EBITDA1 was $1,585 compared to $(446), up $2,031;

[pickuru]

Crescita Reports Q4 and Fiscal 2021 Results

https://finance.yahoo.com/news/crescita-reports-q4-fiscal-20…

1. kursziel 1$

[Nantor]

Ich bin dieses Jahr zum Hoch bei 1 CAD hier eingestiegen, da die Firma mit der Pipeline einiges an Potential hat. Nach den letzten Nachrichten habe ich meine Position heute weiter ausgebaut und meinen Einstieg verbilligt. Crescita hat seinen Vertrieb sowie sein Portfolio weiter ausgebaut. Wenn Crescita so weiter macht wie bisher und seine Pläne umsetzt, wird hier einiges gehen. Ich bin hier erstmal Long drin und werde eventuell auch noch etwas nachlegen, da das Management diese Jahr schon gut geliefert hat. Weiter so!

https://www.stockwatch.com/News/Item/Z-C!CTX-3136811/C/CTX

The alliance with The Best You provides numerous advantages for Crescita:

-Commercial platform to increase sales of its medical and aesthetic brands: Pliaglis, Laboratoire Dr Renaud and Pro-Derm
-Additional opportunities for Crescita's in-licensed medical products: NCTF and Art-Filler
-Participation in the booming medical aesthetics market through The Best You's consolidation strategy
-Insights into end-consumer preferences to fuel product portfolio evolution.

https://www.stockwatch.com/News/Item/Z-C!CTX-3138100/C/CTX

Crescita Therapeutics Inc. has entered into a distribution agreement with Obagi Cosmeceuticals LLC for the exclusive rights to promote, distribute and sell the Obagi Medical product line in Canada.

The Obagi Medical line provides transformational skincare products formulated to minimize signs of aging, address dark spots, hyperpigmentation, fine lines and wrinkles and to protect and enhance skin tone and texture. Crescita will promote and sell the products nationwide through its existing network.

so long
Nantor

[Jim_Panse]

Antwort auf Beitrag Nr.: 69.087.878 von Jim_Panse am 18.08.21 17:37:15

“With this agreement, I am proud to say that now been successful in licensing Pliaglis in 32 countries worldwide, a strategic goal toward which we have been working for the greater part of the last two years,” commented Serge Verreault, President and CEO of Crescita. “Selecting the right commercial partners for Pliaglis is key, and we could not have done better than STADA, a global pharma player with presence in over 120 countries, as well as the required network, resources and expertise to make Pliaglis a success in the MENA region. Pliaglis is currently sold in five countries, and we believe that as launches and sales ramp-up, we could see a meaningful impact on Crescita’s recurring revenue from 2024 onwards,” added Mr. Verreault.